Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma

被引：68

作者：

Binder, M. ^{[1
]}

Rajkumar, S. V. ^{[1
]}

Ketterling, R. P. ^{[2
]}

Greipp, P. T. ^{[2
]}

Dispenzieri, A. ^{[1
]}

Lacy, M. Q. ^{[1
]}

Gertz, M. A. ^{[1
]}

Buadi, F. K. ^{[1
]}

Hayman, S. R. ^{[1
]}

Hwa, Y. L. ^{[1
]}

Zeldenrust, S. R. ^{[1
]}

Lust, J. A. ^{[1
]}

Russell, S. J. ^{[1
]}

Leung, N. ^{[1
,3
]}

Kapoor, P. ^{[1
]}

Go, R. S. ^{[1
]}

Gonsalves, W. I. ^{[1
]}

Kyle, R. A. ^{[1
]}

Kumar, S. K. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, 200 First St SW, Rochester, MN 55905 USA

[2] Mayo Clin, Cytogenet Div, Dept Lab Med & Pathol, Rochester, MN USA

[3] Mayo Clin, Div Nephrol & Hypertens, Rochester, MN USA

来源：

BLOOD CANCER JOURNAL | 2017年 / 7卷

关键词：

STEM-CELL TRANSPLANTATION; INTERNATIONAL STAGING SYSTEM; GENETIC ABNORMALITIES; POOR-PROGNOSIS; DELETION; T(4/14); SURVIVAL; BORTEZOMIB; EXPERIENCE; CONSENSUS;

D O I：

10.1038/bcj.2017.83

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Fluorescence in situ hybridization evaluation is essential for initial risk stratification in multiple myeloma. While the presence of specific cytogenetic high-risk abnormalities (HRA) is known to confer a poor prognosis, less is known about the cumulative effect of multiple HRA. We studied 1181 patients with newly diagnosed multiple myeloma who received novel agents as first-line therapy. High-risk abnormalities were defined as t(4;14), t(14;16), t(14;20) and del(17p). There were 884 patients (75%) without any HRA and 297 patients (25%) with HRA, including 262 (22%) with one HRA and 35 (3%) with two HRA. The presence of one HRA (versus zero, hazard ratio (HR) 1.65, 95% confidence interval (CI) 1.32-2.05, p<0.001) and the presence of two HRA (versus zero, HR 3.15, 95% CI 2.00-4.96, p<0.001) were of prognostic significance after adjusting for other prognostic factors. Abnormalities of chromosome 13 were of prognostic significance independent of the established HRA: Monosomy 13 (HR 1.27, 95% CI 1.04-1.56, P = 0.022) and del (13q) (HR 0.48, 95% CI 0.28-0.81, P = 0.006) with opposite effects. Patients with HRA experienced worse overall survival suggesting a cumulative adverse effect of multiple HRA. Abnormalities of chromosome 13 were of prognostic significance after adjusting for other prognostic factors.

引用

页码：e600 / e600

页数：6

共 33 条

[1]

[Anonymous], BLOOD

[2] Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].

Avet-Loiseau, Herve ;

Attal, Michel ;

Moreau, Philippe ;

Charbonnel, Catherine ;

Garban, Frederic ;

Hulin, Cyrille ;

Leyvraz, Serge ;

Michallet, Mauricette ;

Yakoub-Agha, Ibrahim ;

Garderet, Laurent ;

Marit, Gerald ;

Michaux, Lucienne ;

Voillat, Laurent ;

Renaud, Marc ;

Grosbois, Bernard ;

Guillerm, Gaelle ;

Benboubker, Lotfi ;

Monconduit, Mathieu ;

Thieblemont, Catherine ;

Casassus, Philippe ;

Caillot, Denis ;

Stoppa, Anne-Marie ;

Sotto, Jean-Jacques ;

Wetterwald, Marc ;

Dumontet, Charles ;

Fuzibet, Jean-Gabriel ;

Azais, Isabelle ;

Dorvaux, Veronique ;

Zandecki, Marc ;

Bataille, Regis ;

Minvielle, Stephane ;

Harousseau, Jean-Luc ;

Facon, Thierry ;

Mathiot, Claire .

BLOOD, 2007, 109 (08) :3489-3495

[3] Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) [J].

Avet-Loiseau, Herve ;

Leleu, Xavier ;

Roussel, Murielle ;

Moreau, Philippe ;

Guerin-Charbonnel, Catherine ;

Caillot, Denis ;

Marit, Gerald ;

Benboubker, Lotfi ;

Voillat, Laurent ;

Mathiot, Claire ;

Kolb, Brigitte ;

Macro, Margaret ;

Campion, Loic ;

Wetterwald, Marc ;

Stoppa, Anne-Marie ;

Hulin, Cyrille ;

Facon, Thierry ;

Attal, Michel ;

Minvielle, Stephane ;

Harousseau, Jean-Luc .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4630-4634

[4] Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma [J].

Binder, Moritz ;

Rajkumar, S. Vincent ;

Gertz, Morie A. ;

Lacy, Martha Q. ;

Dispenzieri, Angela ;

Buadi, Francis K. ;

Dingli, David ;

Hayman, Suzanne R. ;

Lust, John A. ;

Kapoor, Prashant ;

Lin, Yi ;

Go, Ronald S. ;

Hwa, Yi L. ;

Kyle, Robert A. ;

Kumar, Shaji K. .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (10) :888-891

[5] A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial [J].

Boyd, K. D. ;

Ross, F. M. ;

Chiecchio, L. ;

Dagrada, G. P. ;

Konn, Z. J. ;

Tapper, W. J. ;

Walker, B. A. ;

Wardell, C. P. ;

Gregory, W. M. ;

Szubert, A. J. ;

Bell, S. E. ;

Child, J. A. ;

Jackson, G. H. ;

Davies, F. E. ;

Morgan, G. J. .

LEUKEMIA, 2012, 26 (02) :349-355

[6] Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/Ho95 MM trial) [J].

Cavo, Michele ;

Palumbo, Antonio ;

Zweegman, Sonja ;

Dimopoulos, Meletios A. ;

Hajek, Roman ;

Pantani, Lucia ;

Beksac, Meral ;

Wester, Ruth ;

Johnsen, Hans E. ;

Mellqvist, Ulf -Henrik ;

Petrucci, Maria Teresa ;

Driessen, Christoph ;

Di Raimondo, Francesco ;

Troia, Rossella ;

Pezzi, Annalisa ;

Van der Holt, Bronno ;

Wu, Ka Lung ;

Ludwig, Heinz ;

Gay, Francesca ;

Sonneveld, Pieter .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[7] p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation [J].

Chang, H ;

Qi, C ;

Yi, QL ;

Reece, D ;

Stewart, AK .

BLOOD, 2005, 105 (01) :358-360

[8] The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant [J].

Chang, H ;

Sloan, S ;

Li, D ;

Zhuang, LH ;

Yi, QL ;

Chen, CI ;

Reece, D ;

Chun, K ;

Stewart, AK .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) :64-68

[9] IMWG consensus on risk stratification in multiple myeloma [J].

Chng, W. J. ;

Dispenzieri, A. ;

Chim, C-S ;

Fonseca, R. ;

Goldschmidt, H. ;

Lentzsch, S. ;

Munshi, N. ;

Palumbo, A. ;

Miguel, J. S. ;

Sonneveld, P. ;

Cavo, M. ;

Usmani, S. ;

Durie, B. G. M. ;

Avet-Loiseau, H. .

LEUKEMIA, 2014, 28 (02) :269-277

[10]

COX DR, 1972, J R STAT SOC B, V34, P187

← 1 2 3 4 →